Table 2. Case series stratified by individual patients.
| Variable | Patient | ||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Age (y) | 46 | 72 | 58 | 79 | 64 | 62 | 60 |
| Sex | Male | Male | Male | Male | Male | Male | Male |
| BMI (kg/m2) | 18.1 | 22.2 | 29.4 | 25.1 | 23.8 | 31.6 | * |
| ASA | 2 | 2 | 2 | 3 | 1 | 1 | 1 |
| Charlson Comorbidity | 3 | 6 | 3 | 6 | 4 | 4 | 3 |
| Colorectal malignancy | Primary rectal Ca | Primary rectal Ca | None | Rectal Ca recurrence | Primary rectal Ca | Primary rectal Ca | None |
| Urological malignancy | None | None | Primary prostate Ca | Primary prostate Ca | Primary prostate Ca | Primary prostate Ca | Primary prostate Ca |
| Pre-op PSA | None | None | * | 4.5 | 8.1 | 18 | 28 |
| T (CR/URO for dual) | 4 | 4a | 4 | 4b/2c | 1/3a | 2/3a | 4 |
| N | 2a | 0 | 0 | 1 | 0 | 0 | 1 |
| M | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Surgery | APR+CP+IC | APR+prostatectomy | APR+cystectomy+IC | APR+CP+IC | ULAR+prostatectomy | APR+prostatectomy | ULAR+prostatectomy |
| Urological anastomosis | Ileal-ileal | Vesicourethral | Ileal-ileal | Ileal-ileal | Vesicourethral | Vesicourethral | Vesicourethral |
| Colorectal anastomosis | None | None | None | None | Colorectal | None | Colorectal |
| Stoma | End-colostomy+urostomy | End-colostomy | End-colostomy+urostomy | End-colostomy+urostomy | Loop ileostomy | End colostomy | Loop ileostomy |
| Operation time (min) | 200 | 450 | 600 | 600 | 420 | 670 | 460 |
| EBL (mL) | * | * | * | 400 | 150 | 1,000 | 700 |
| LOS (d) | 9 | 13 | 12 | 34 | 8 | 6 | * |
| Clavien–Dindo complication | II | I | I | II | I | I | III |
| Morbidity | Recurrent UTI requiring IVABx. R) Ureteric stricture requiring stent | Ileus | Ileus | Ileus, perineal wound dehiscence/infection (VAC and IVABx) | UTI (POABx) | Ileus | Vesicourethral anastomotic leak and sepsis |
| Post-op transfusion | No | No | No | No | No | No | No |
| Colorectal histology | Adenocarcinoma | Adenocarcinoma (high grade) | None | Adenocarcinoma (high grade) | Adenocarcinoma | Adenocarcinoma | None |
| Urological histology | None | None | Prostate adenocarcinoma (high grade) | Prostate adenocarcinoma | Prostate adenocarcinoma | Prostate adenocarcinoma | Prostate adenocarcinoma |
| Lymph nodes positive | 4/12 | 0/13 | 0/0 | 1/8 | 0/15 | 0/13 | 4/12 |
| Grade of TME | 3 | 3 | 3 | 3 | 2 | 3 | 3 |
| Colorectal margins CRM (mm) | 4 | 0.7 | None | 3.5 | 3 | 8 | None |
| Colorectal margins DRM (mm) | 100 | 35 | Clear, mm not reported | Clear, mm not reported | 10 | 15 | Clear, mm not reported |
| Urological margins | None | None | Clear | Clear | Clear | Clear | Clear |
| Neo-adjuvant therapy/response | Yes/Grade 3 | Yes/Grade 1 | No | Yes/Grade 3 | No | Yes/Grade 1 | Yes/Grade 1 |
| Type of therapy | Chemoradiotherapy | Chemoradiotherapy | None | Chemoradiotherapy+5-FU | Chemoradiotherapy (45 Gy XRT and 5-FU) | Chemoradiation 5-FU+45 Gy XRT | ADT |
| Adjuvant therapy | Yes | Yes | No | Yes | No | Yes | No |
| Type of therapy | Modified FOLFOX-6 | 5-FU | None | 5-FU | None | Capecitabine incomplete course | None |
| Recurrence (months post-op) | 21 | None | 22 | 24 | None | None | None |
| Recurrence (local) | None | None | Right internal iliac node | Pelvic | None | None | None |
| Recurrence (systemic) | Retrocrural/supraclavicular nodes, lung | None | Thoracic vertebrae | Lung, femoral neck | None | None | None |
| Survival | Yes | Yes | Yes | No | Yes | Yes | Yes |
Grade 3 is considered complete. Grade 2 is considered near complete. Response to neoadjuvant therapy adjudged by grades where Grade 1 is moderate response and Grade 3 is poor response. BMI, body mass index; ASA, American Society of Anesthesiologists; Ca, cancer; op, operative; PSA, prostate specific antigen; CR/URO, colorectal or urological; ARP, abdominoperineal resection; ULAR, ultra-low anterior resection; CP, cystoprostatectomy; IC, ileal conduit; EBL, estimated blood loss; LOS, length of stay; UTI, urinary tract infections; IVABx, intravenous antibiotics; VAC, vacuum dressing; POABx, per oral antibiotics; TME, total mesorectal excision; CRM, circumferential resection margin; DRM, distal resection margin; XRT, external beam radiotherapy; FU, Fluorouracil; ADT, androgen deprivation therapy; FOLFOX, folinic acid, fluorouracil, oxaliplatin.
*Denotes missing data.